A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost - PubMed (original) (raw)
doi: 10.1215/15228517-2007-053. Epub 2008 Feb 20.
Michael R Zalutsky, Gamal Akabani, R Edward Coleman, Allan H Friedman, James E Herndon 2nd, Roger E McLendon, Charles N Pegram, Jennifer A Quinn, Jeremy N Rich, James J Vredenburgh, Annick Desjardins, Sridharan Guruangan, Susan Boulton, Renee H Raynor, Jeanette M Dowell, Terence Z Wong, Xiao-Guang Zhao, Henry S Friedman, Darell D Bigner
Affiliations
- PMID: 18287339
- PMCID: PMC2613820
- DOI: 10.1215/15228517-2007-053
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
David A Reardon et al. Neuro Oncol. 2008 Apr.
Abstract
The purpose of this study was to determine the feasibility and assess the efficacy and toxicity, among newly diagnosed malignant glioma patients, of administering (131)I-labeled murine antitenascin monoclonal antibody 81C6 ((131)I-81C6) into a surgically created resection cavity (SCRC) to achieve a patient-specific, 44-Gy boost to the 2-cm SCRC margin. A radioactivity dose of (131)I-81C6 calculated to achieve a 44-Gy boost to the SCRC was administered, followed by conventional external beam radiotherapy (XRT) and chemotherapy. Twenty-one patients were enrolled in the study: 16 with glioblastoma multiforme (GBM) and 5 with anaplastic astrocytoma. Twenty patients received the targeted 44-Gy boost (+/-10%) to the SCRC. Attributable toxicity was mild and limited to reversible grade 3 neutropenia or thrombocytopenia (n = 3; 14%), CNS wound infections (n = 3; 14%), and headache (n = 2; 10%). With a median follow-up of 151 weeks, median overall survival times for all patients and those with GBM are 96.6 and 90.6 weeks, respectively; 87% of GBM patients are alive at 1 year. It is feasible to consistently achieve a 44-Gy boost dose to the SCRC margin with patient-specific dosing of (131)I-81C6. Our study regimen ((131)I-81C6 + XRT + temozolomide) was well tolerated and had encouraging survival. To determine if selection of good-prognosis patients affects outcome associated with this approach, the U.S. Food and Drug Administration has approved a trial randomizing newly diagnosed GBM patients to either our study regimen or standard XRT plus temozolomide.
Figures
Fig. 1
Kaplan-Meier overall survival estimates for all patients following stratification by histology.
References
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. - PubMed
- Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572 – 2578. - PubMed
- Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys. 1992;24:55 – 57. - PubMed
- Reardon DA, Akabani G, Coleman RE, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006;24:115 – 122. - PubMed
- Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20:1389 – 1397. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50 CA108786/CA/NCI NIH HHS/United States
- P50 NS020023/NS/NINDS NIH HHS/United States
- 1P50 CA 108786-01/CA/NCI NIH HHS/United States
- CA 11898/CA/NCI NIH HHS/United States
- NS 20023/NS/NINDS NIH HHS/United States
- R37 CA011898/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical